Loading
Latest filing published 23 Dec 2025 for Protalix BioTherapeutics, Inc., €86k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Dror Bashan in Protalix BioTherapeutics, Inc., where the filings describe the role as chief executive. We count 10 filings; the first trade dates from 11 August 2020 and the latest from 19 December 2025.
No open-market sale appears; the market trades are 4 purchases worth €266k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 6 share grants. In 2025 alone, the filings show 1 purchase and no sales.
In size, the median ticket on the buying side is €75k. No cluster: in 4 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 23 December 2025, reports an open-market purchase of €86k in Protalix BioTherapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations